foxo4 dri peptide senolytic human trial Molecular modelling of the FOXO4-TP53 interaction to design peptides for the elimination of senescent cancer cells FOX04-DRI - Apollo Peptide Sciences
FOX04 DRI Apollo Peptide Sciences FOXO4 DRI 10mg Ion Peptide The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications Molecular modelling of the FOXO4 TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells ScienceDirect
Pay in 4 interest-free payments of $7.33 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6



